The estimated Net Worth of Curran Simpson is at least $8.33 Million dollars as of 1 August 2024. Mr. Simpson owns over 100 units of Regenxbio Inc stock worth over $2,161,170 and over the last 9 years he sold RGNX stock worth over $4,270,408. In addition, he makes $1,901,140 as Senior Vice President - Product Development and Chief Technology Officer at Regenxbio Inc.
Curran has made over 18 trades of the Regenxbio Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 100 units of RGNX stock worth $1,500 on 1 August 2024.
The largest trade he's ever made was exercising 62,309 units of Regenxbio Inc stock on 16 October 2018 worth over $1,314,097. On average, Curran trades about 11,789 units every 81 days since 2015. As of 1 August 2024 he still owns at least 170,037 units of Regenxbio Inc stock.
You can see the complete history of Mr. Simpson stock trades at the bottom of the page.
Curran M. Simpson serves as Senior Vice President - Product Development, Chief Technology Officer of the Company. He is currently our Senior Vice President, Product Development and Chief Technology Officer, and served as our Senior Vice President, Technical Operations from August 2015 to August 2018. Prior to joining us, Mr. Simpson was the Regional Supply Chain Head for North America at GlaxoSmithKline plc (“GSK”), a pharmaceutical company, from December 2012 until August 2015. Mr. Simpson was the Senior Vice President, Operations at the Human Genome Sciences division of GSK (“HGS”) from July 2006 to December 2012, as well as the Vice President, Manufacturing Operations at HGS from January 2003 to June 2006. Prior to HGS, Mr. Simpson held various positions with Biogen, Inc., Covance Biotechnology Services Inc., Novo-Nordisk Biochem Inc., Genentech, Inc. and Genencor, Inc. Mr. Simpson received an M.S. in Surface and Colloid Science (Physical Chemistry) from Clarkson University and a B.S. in Chemistry/Chemical Engineering from Clarkson College of Technology.
As the Senior Vice President - Product Development and Chief Technology Officer of Regenxbio Inc, the total compensation of Curran Simpson at Regenxbio Inc is $1,901,140. There are 4 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
Curran Simpson is 58, he's been the Senior Vice President - Product Development and Chief Technology Officer of Regenxbio Inc since 2018. There are 11 older and 8 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
Curran's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Regenxbio Inc executives and other stock owners filed with the SEC include: